Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
Increased biogenic catecholamine and metabolite levels in two patients with malignant catatonia
Authors Nisijima K
Received 20 June 2013
Accepted for publication 24 July 2013
Published 12 August 2013 Volume 2013:9 Pages 1171—1174
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Department of Psychiatry, Jichi Medical University, Tochigi, Japan
Abstract: The pathophysiology of malignant catatonia, a rare life-threatening psychiatric syndrome, has not yet been elucidated. This paper reports on two patients with malignant catatonia who showed elevated urinary or plasma catecholamine levels. Patient 1 had high catecholamine and metabolite levels in a 24-hour urine sample, and patient 2 had elevated plasma catecholamine levels. These findings indicate the presence of peripheral sympathetic nervous system hyperactivity in malignant catatonia. Symptoms of autonomic dysfunction, including tachycardia, labile blood pressure, and diaphoresis, are typical features of malignant catatonia and may be related to the increased levels of biogenic amines in these cases. Although the findings in the present study cannot entirely explain the pathophysiology of malignant catatonia, they do indicate that hyperactivity of the sympathetic nervous system may be involved in the pathology of this condition.
Keywords: malignant catatonia, catecholamine levels, neuroleptic malignant syndrome
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.